Solara Active Pharma Sciences Ltd
NSE:SOLARA
Decide at what price you'd be comfortable buying and we'll help you stay ready.
|
SEI Investments Co
NASDAQ:SEIC
|
US |
|
Barrett Business Services Inc
NASDAQ:BBSI
|
US |
|
K
|
Kyoden Co Ltd
TSE:6881
|
JP |
|
C
|
Chiu Ting Machinery Co Ltd
TWSE:1539
|
TW |
|
C
|
Crystal Growth&Energy Equipment Co Ltd
SSE:688478
|
CN |
|
Computer Modelling Group Ltd
TSX:CMG
|
CA |
|
Pae Ltd
BSE:517230
|
IN |
Gross Margin
Gross Margin shows how much money a company keeps from each dollar of sales after paying for the products it sells. It tells how profitable the company`s core business is before other expenses.
Gross Margin shows how much money a company keeps from each dollar of sales after paying for the products it sells. It tells how profitable the company`s core business is before other expenses.
Peer Comparison
| Country | Company | Market Cap |
Gross Margin |
||
|---|---|---|---|---|---|
| IN |
|
Solara Active Pharma Sciences Ltd
NSE:SOLARA
|
21.2B INR |
Loading...
|
|
| US |
|
Eli Lilly and Co
NYSE:LLY
|
853.2B USD |
Loading...
|
|
| US |
|
Johnson & Johnson
NYSE:JNJ
|
566.5B USD |
Loading...
|
|
| CH |
|
Roche Holding AG
SIX:ROG
|
243.4B CHF |
Loading...
|
|
| UK |
|
AstraZeneca PLC
LSE:AZN
|
214.2B GBP |
Loading...
|
|
| US |
|
Merck & Co Inc
NYSE:MRK
|
288B USD |
Loading...
|
|
| CH |
|
Novartis AG
SIX:NOVN
|
225.4B CHF |
Loading...
|
|
| IE |
E
|
Endo International PLC
LSE:0Y5F
|
237.1B USD |
Loading...
|
|
| DK |
|
Novo Nordisk A/S
CSE:NOVO B
|
1.1T DKK |
Loading...
|
|
| US |
|
Pfizer Inc
NYSE:PFE
|
153.3B USD |
Loading...
|
|
| US |
|
Bristol-Myers Squibb Co
NYSE:BMY
|
115.5B USD |
Loading...
|
Market Distribution
| Min | -3 052.3% |
| 30th Percentile | 26.9% |
| Median | 39% |
| 70th Percentile | 53.3% |
| Max | 8 269.1% |
Other Profitability Ratios
Solara Active Pharma Sciences Ltd
Glance View
Solara Active Pharma Sciences Ltd. engages in the manufacture and development of active pharmaceutical ingredient. The company is headquartered in Chennai, Tamil Nadu. The company went IPO on 2018-06-27. The firm is involved in contract manufacturing and development services for global companies. Its commercial products include Aprepitant (Antiemetic), Brivaracetam (Antiepileptic), Bumetanide (Inj) (Loop Diuretic), Buspirone Hcl (Anxiolytic), Cevimeline Hydrochloride (Muscarinic Agonist), Cinacalcet Hydrochloride (Calcimimetic Agent), Citicoline Sodium (Anticonvulsant), Colchicine (Antigout Agent), Disulfiram (Chronic Alcoholism), Edaravone (Recovery Of Stroke), Etomidate (Anesthetics), Felbamate (Anticonvulsant), Flecainide Acetate (Anti-Arrhythmic Agent), Rifaximin (Antibiotic), S-Ibuprofen (Anti-Inflammatory), Oseltamivir Phosphate(Antiviral) and Levetiracetam (Anticonvulsant). The company provides services, such as synthetic development, analytical development, process engineering, and regulatory services.
See Also
Gross Margin is calculated by dividing the Gross Profit by the Revenue.
The current Gross Margin for Solara Active Pharma Sciences Ltd is 51.8%, which is above its 3-year median of 43.6%.
Over the last 3 years, Solara Active Pharma Sciences Ltd’s Gross Margin has increased from 41.7% to 51.8%. During this period, it reached a low of 25.6% on Mar 31, 2024 and a high of 54.1% on Sep 30, 2025.
